Ann: Appointment of Executive Director Dr Michael Thurn, page-9

Our Michael Thurn certainly has a fantastic, hands on approach to everything he does and his ability to value add has been seen with other biotechs. While Novartis are not interested in our coming news regarding three aspects of cbd use, there is no doubt that interest exists with other pharmas. They will undoubtedly be anxious for our phase 2 results.

Then a game of poker could occur, but also could the ability of raising funds for phase 3. There seems to be many pharma IPO's on Wall Street raising some serious money, so surely nothing can be dismissed.